Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.

Background: Effective psoriasis therapies are needed for long-term symptom control.

Objective: Assess efalizumab (Raptiva) efficacy in a large cohort of psoriasis patients.

Methods: Data from three Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter studies were pooled.

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.

Background: Efalizumab targets T cell-mediated steps important in psoriasis immunopathogenesis.

Objective: We sought to evaluate the efficacy and safety of efalizumab retreatment in patients with moderate to severe plaque psoriasis.

Methods: In this open-label, phase III study, 365 patients who received efalizumab therapy during an earlier clinical trial were retreated with 12 weeks of subcutaneous efalizumab (1 mg/kg/wk) 35 days or more after their last dose of efalizumab.

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.

Background: Efalizumab is a T cell-targeted therapy for psoriasis.

Objective: We sought to evaluate the efficacy and safety of long-term, continuous efalizumab therapy.

Methods: Of 339 patients enrolled in this ongoing, open-label, phase III study, after 3 months 290 qualified for and entered the maintenance treatment phase.

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

Background: Efalizumab inhibits multiple T-cell-mediated processes.

Objective: To evaluate 12- and 24-week efalizumab therapy for psoriasis.

Methods: In this phase III, randomized, double-blind trial, 498 patients received subcutaneous 1 or 2 mg/kg/wk efalizumab or placebo for 12 weeks.